ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
Open access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Optimized post-GWAS analysis identifies therapeutic targets for essential thrombocythemia and polycythemia vera.Communications medicine · 2026Article
- Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors.NAR cancer · 2025Review
- Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options.HemaSphere · 2025Review
- Clinical approaches to overcome PARP inhibitor resistance.Molecular cancer · 2025Review
- PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.British journal of cancer · 2024Article
- Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.Cancers · 2023Review
- Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.International journal of hematology · 2023Article
- Oxidative DNA Damage-induced PARP-1-mediated Autophagic Flux Disruption Contributes to Bupivacaine-induced Neurotoxicity During Pregnancy.Current neuropharmacology · 2023Article
- Review
- Review
- Synthesis of Morpholine-, Piperidine-, andACS pharmacology & translational science · 2022Article
- Article
- Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.Journal of hematology & oncology · 2022Review
- Review
- Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment.Experimental hematology & oncology · 2021Review
- Review
- Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.Current hematologic malignancy reports · 2021Review
- PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.Blood reviews · 2021Review
- Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors.Bioorganic chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Keith W PratzSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. Kpratz1@jhmi.edu.
Michelle A RudekSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Ivana GojoSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Mark R LitzowMayo Clinic, Rochester, Minnesota.
Michael A McDevittSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Jiuping JiNational Clinical Target Validation Laboratory, Frederick National Laboratory for Cancer Research, Bethesda, Maryland.
Larry M KarnitzMayo Clinic, Rochester, Minnesota.
James G HermanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Robert J KindersFrederick National Laboratory for Cancer Research, Frederick, Maryland.
B Douglas SmithSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Steven D GoreSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Hetty E CarrawaySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Margaret M ShowelSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Douglas E GladstoneSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Mark J LevisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Hua-Ling TsaiSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Gary RosnerSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Alice ChenIDB/CTEP/NCI, National Cancer Institute, Rockville, Maryland.
Scott H KaufmannMayo Clinic, Rochester, Minnesota.
Judith E KarpSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Mayo Clinic · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MThe Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9MPHASE I CLINICAL TRIALS OF ANTICANCER AGENTSU01CA069912 · NCI · MAYO CLINIC ROCHESTER · PI ERLICHMAN, CHARLES · 1995 to 2013
$10.1MPHASE I TRIALS OF ANTICANCER AGENTSU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARDUCCI, MICHAEL A · 1995 to 2013
$8.6MPhase 2 Clinical Trials Program for Experimental Therapeutics Clinical Trials NetworkUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ADJEI, ALEX A. · 2014 to 2019
$5.3MWisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI JABBOUR, SALMA, LIU, GLENN · 2014 to 2019
$4.1MTargeting Chk1 in Acute Myeloid LeukemiaR01CA190473 · NCI · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2015 to 2019
$1.8MCCR NIH HHS HHSN261200800001CNCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001863NCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA006973NCI NIH HHS R01 CA190473NCI NIH HHS U01 CA069912NCI NIH HHS U01 CA070095NCI NIH HHS UM1 CA186686NCI NIH HHS UM1 CA186691NCI NIH HHS UM1 CA186716
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedBenzimidazolesCarboplatinDisease-Free SurvivalDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsFanconi Anemia Complementation Group D2 ProteinFemaleHumansLeukemia, Biphenotypic, AcuteLeukemia, Myelomonocytic, ChronicMaleMiddle AgedMyeloproliferative DisordersPoly (ADP-Ribose) Polymerase-1BenzimidazolesCarboplatinFANCD2 protein, humanFanconi Anemia Complementation Group D2 ProteinPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Topotecanveliparib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.